Switching From Generic Selective Serotonin Reuptake Inhibitors (SSRIs) and Selective Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) to Three Different Dose Initiation Strategies With Vilazodone

PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 31, 2012

Primary Completion Date

December 31, 2013

Study Completion Date

December 31, 2013

Conditions

Major Depressive Disorder (MDD)

Interventions

DRUG

Vilazodone

All subjects will receive Vilazodone at 10, 20 or 40mg.

Trial Locations (1)

Duke University Medical Center / Civitan Building, Durham